🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — May 08, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (Q1 2026 focus), overarching themes reveal mixed corporate performance with 14/25 quarterly reporters showing YoY revenue growth averaging +25% in outperformers like Monster Beverage (+26.9%), Vistra (+43%), CoreWeave (+111.6%), and AMN Healthcare (+100%), contrasted by declines averaging -6% in laggards like Saga Communications (-5.6%), Sylvamo (-8%), and Goldman Sachs BDC (income -8.5% QoQ). Margin compression affected 12/25 companies (avg -200bps, e.g., AdvanSix 1.2% vs 13.7%, Ziff Davis EBITDA -11.2%), driven by higher costs, weather, and one-offs, while capital returns strengthened with $1.4B+ in buybacks (e.g., Republic $317M, Vistra $372M, Yum China $218M) and steady dividends (e.g., Kodiak $0.49, Princeton flat $0.12). M&A activity surged with 5 deals/LOIs (TOMI $120M EV merger, RE/MAX merger, Two Harbors cash up to $12/share, TDS Array proposal), signaling consolidation; biotech/healthcare highlighted pipeline catalysts (Artiva Phase 3 H2 2026). Institutional 13Fs showed concentrated bets on tech/semiconductors (e.g., Act Two MSFT/AAPL, Central Asset semis). Implications: Favor growth sectors like energy/tech/staffing for portfolios, monitor margin pressures and Q2 guidance for cyclicals.

26 high priority 24 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 08, 2026

Across 50 SEC filings for May 8, 2026, mixed Q1/FY results dominate with 70% showing revenue growth (avg +15% YoY in high performers like Cloudflare +33.5%, Monster +26.9%, Astrana +56%) but frequent profitability pressures from higher opex/costs (e.g., 8/15 quarters with wider losses, avg operating margin compression -150bps). Capital allocation trends bullish with 12 companies announcing/raising dividends (e.g., Innospec +10%, Grainger +10%) and buybacks (e.g., News Corp $1B program, Itron $200M new), while financings raised $200M+ in biotech/aero (Cellectar $35M, New Horizon $20M). Energy/mining pivot to AI notable (IREN $3.4B NVIDIA deal), REITs face vacancies dragging AFFO -6% avg. Forward guidance mixed: 6 raises (Grainger EPS +5%, OSS rev +20-25%), 2 cuts/deferrals (Ziff Davis deferred). Portfolio implication: Favor growth names with strong cash flow (e.g., Republic Services OCF +20%), monitor debt rises (Ducommun +25%, IREN convertibles x4). Sector rotation opportunity from traditional energy to AI infra.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 08, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary stream (including adjacent sectors like tech, gaming, and REITs), Q1 2026 results show mixed performance with 12/20 quarterly reporters posting YoY revenue growth averaging +17% (led by Cloudflare +33.5%, Fortinet +20.1%, DraftKings +17%, Array Digital +93%), but 8 experiencing declines averaging -6% (Ultralife -6.5%, Ziff Davis -1.9%, Fluor -8%). Margin compression is prevalent in 10/15 cases (avg -100bps), offset by strong capital returns including $2.5B+ in buybacks (Fortinet $823M, Yum China $218M, Topgolf $42M) and steady dividends (Strawberry Fields REIT $0.17/share). Divestitures generated $2B+ in gains/cash (Fluor NuScale $1.4B, Array spectrum $1B+), boosting liquidity amid operating losses in 9/20 firms. Forward guidance mixed: raised by Interface (+2% FY sales), deferred by Ziff Davis, reaffirmed by DraftKings/Enbridge. IPO activity (Applied Aerospace, Fervo Energy) signals growth optimism, while Nasdaq compliance risks (Profusa) and litigation hits (Burford -$1.6B) highlight volatility. Portfolio-level trend: digital/gaming outperforming traditional retail/manufacturing, with buybacks signaling management conviction despite macro pressures.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 08, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (though heavily featuring financials, REITs, and 13Fs with limited pure healthcare plays), Q1 2026 period-over-period trends reveal robust revenue growth averaging +15-20% YoY in reporting firms like AbbVie (+12.4%), CoreWeave (+111.6%), Paylocity (+10.5%), and banks (e.g., Peapack-Gladstone NII +32%), but net income volatility with 6/12 mixed earners showing compressions (e.g., AbbVie NI -46%, Citizens & Northern -96%) due to higher provisions, R&D, and expenses. Healthcare highlights include Cellectar Biosciences' $35M raise for Phase 3 trial amid strong Phase 2b data (83.6% ORR), Edwards Lifesciences' strong AGM support (>88%), and AbbVie's revenue beat offset by IPR&D costs. Capital allocation trends favor dividends (CBL +39% to $0.625/share, NewLake 90% AFFO payout) and buybacks (News Corp $456M YTD), with 13Fs signaling institutional conviction in tech (NVIDIA, Apple top holdings across 20+ filers). Portfolio-level patterns show margin pressures in high-growth (avg -100bps implied) vs. stability in banks; actionable now: pivot to funded biotechs and dividend hikes amid mixed guidance.

18 high priority 32 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 08, 2026

Across 15 DEF 14A proxy statements filed around May 8, 2026, the dominant theme is routine annual shareholder meetings in June 2026 focused on director elections, auditor ratifications, and advisory votes on executive compensation, with 12/15 featuring board elections or renewals signaling governance continuity. Period-over-period financial trends are sparse but highlight resilience in apparel (PVH Corp revenue growth amid macro challenges, 8.8% non-GAAP margins despite -80 bps tariff hit, $560M shareholder returns) contrasted by edtech weakness (Skillsoft FY2026 revenue -3% YoY to $513M, net loss widened to $140M). Mixed sentiments prevail in 3 filings, driven by SPAC extension risks (Rising Dragon high prior redemptions of 5.7M shares at $10.63 vs $7.63 market price) and fund strategy shifts (John Hancock non-diversified status increases concentration risk). Capital allocation leans positive with PVH's repurchases and Criteo's buyback authorizations, while forward-looking catalysts cluster in mid-June meetings for potential equity plan approvals and governance changes like board declassifications (NRC, nCino). No widespread insider trading activity noted, but sponsor deposits in Rising Dragon indicate management conviction. Overall, low materiality (avg 6.5/10) suggests stable but unexciting proxy season, with alpha in governance upgrades and SPAC extension outcomes.

15 high priority 15 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 08, 2026

A surge of 11 regulatory filings on May 8, 2026, highlights a robust IPO pipeline dominated by emerging growth companies across quantum tech (Quantinuum), aerospace/defense (Applied Aerospace), insurance (Safepoint), biotech (DRC Medicine, Akari, Vaxart, First Tracks), software (Smith Micro), consumer finance (1st Franklin), and construction/SPAC (Suncrete), with 6 traditional IPO S-1s, 2 debt shelf offerings, 2 resale registrations, and 1 SPAC merger S-4. Period-over-period insights reveal modest share dilution at Vaxart (242M vs 240M shares outstanding QoQ) and discontinued real estate loan originations at 1st Franklin since 2024 with $79.3M credit availability vs $220.7M borrowed as of Dec 31, 2025, signaling stable but leveraged finance ops. Forward-looking catalysts include Nasdaq compliance deadlines (Smith Micro June 22), SPAC combo votes (DRC), business combination deadlines (Suncrete July 28), and annual meetings (Smith Micro May 26), amid mixed sentiment with 1 positive (Applied), 2 negative/mixed distress signals, and neutral tones elsewhere. Portfolio-level trends show high materiality (avg 9/10) for IPOs but dilution risks in biotech (Akari 123.9% new ADSs) and going concern doubts (Suncrete), positioning investors for pre-IPO alpha in defense/insurance while monitoring biotech/software risks. No insider trading or capex allocation patterns detected across filings, but recent acquisitions (Applied) and cash runways (Akari to mid-2027) provide relative strength signals.

11 high priority 11 total filings
· daily

Global High-Priority Regulatory Events — May 08, 2026

Across 50 filings for May 8, 2026, focused on global high-priority events, dominant themes include mixed Q1 2026 earnings with revenue growth averaging +20% YoY in high performers like Cloudflare (+33.5%), Astrana Health (+56%), and Vistra (+43%) offset by declines in Virtus (-8.4%) and flat Watsco (0.1%), alongside a wave of Indian insolvencies (Quadrant Televentures, Kallam Textiles, Prime Focus, Jindal Poly) signaling distress in textiles/telecom. Capital raises were prominent (Cellectar $35M, New Horizon $20M) funding trials and aircraft programs, while buybacks (Garware Technical Fibres ₹110 Cr, Republic Services $317M) and repurchases (Monster $134M, Yum China $218M) indicate shareholder returns amid mixed margins (compression in 12/20 10-Qs averaging -100 bps). Positive catalysts include Phase 3 trial funding and strong ORR data (Cellectar 83.6%), but risks from delisting threats (Smith Micro Nasdaq extension to June 22) and widening losses (IREN $248M Q3 net loss) prevail. Sector patterns show healthcare/biotech outperformance vs. manufacturing distress; overall sentiment mixed (24/50), with 10 insolvencies/regulatory actions demanding vigilance. Actionable now: Favor growth names with buybacks, avoid Indian insolvency names.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 08, 2026

Across 50 Q1 2026 filings, results were predominantly mixed (45/50), with revenue growth averaging ~20% YoY in high performers like tech (Cloudflare +33.5%, CoreWeave +111.6%, Fortinet +20.1%) and healthcare (Astrana +56%, AMN +100%, Natera +38.8%), but declines in media (Saga -5.6%, Nu Skin -12.1%), REITs (NewLake -7%), and select financials (DXC -1.8%). Net income trends showed sharp improvements in outperformers (Monster +28.6%, Vistra from loss to +$1B, Yum China +5.8%) offset by widening losses elsewhere (IREN -$248M, Gran Tierra -$119M), with margin compression common (avg -50 bps in 12/50) due to rising opex/SG&A. Capital allocation leaned bullish with aggressive buybacks totaling >$3B (Fortinet $823M, Republic $317M, Yum China $218M, Vistra $372M) signaling management conviction, while 8 companies issued equity/diluted shares. Cash flows improved in 28/50 (e.g., Republic +19.7% to $1.2B), but capex surges (Ameren +48%, CoreWeave $7.7B) and impairments pressured balance sheets. Portfolio implications favor selective longs in growth tech/healthcare/energy amid broader caution on cyclicals/media; watch buyback acceleration as stabilizer.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 08, 2026

A cluster of 5 small-cap companies, primarily in healthcare and biotech sectors, received regulatory notices between May 4-8, 2026, for failing Nasdaq or NYSE American minimum $1.00 bid price requirements over 30 consecutive business days from late March to early May 2026, signaling acute share price distress and delisting risks. CCEL stands out as the sole outlier with an accepted compliance plan granting a 17-month extension to September 9, 2027, versus standard 180-day periods ending November 2-4, 2026 for DFNS, HUMA, and RMTI, and an immediate delisting determination for ADTX due to prior reverse splits. No period-over-period financial trends (e.g., revenue YoY/QoQ) or insider trading activity were detailed in filings, but forward-looking compliance deadlines create a tight catalyst calendar. Predominant negative sentiment (4/5 filings) and high materiality (avg 9/10) underscore portfolio-level pressure on micro-caps, with potential reverse stock splits and appeals as mitigation paths. Market implications include heightened volatility, dilution risks from reverse splits, and possible OTC delistings, pressuring liquidity and valuations. Absence of capital allocation updates (dividends/buybacks) suggests focus on survival over shareholder returns.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 08, 2026

Across 47 filings in the USA Corporate Distress & Bankruptcy stream, a prominent theme is Nasdaq compliance distress with 5 companies (Nukkleus, Aditxt, Humacyte, Rockwell Medical, Cryo-Cell) receiving delisting notices or extensions due to sub-$1 bid prices over 30 consecutive days, signaling valuation weakness and liquidity strains without explicit YoY/QoQ declines but amid dilutive raises. Counterbalancing this, 20+ filings highlight capital raises via equity offerings, warrant exchanges, and ATM programs (e.g., Cellectar $35M, New Horizon $20M, Galaxy Digital $500M ATM), providing liquidity but risking further dilution; no period-over-period revenue/margin data disclosed, but operational metrics like Cellectar's 83.6% ORR show pockets of strength. M&A and deal activity remains resilient with premium increases (Two Harbors to $12/share, 21% premium) and large contracts (Digi Power X $1.1B MSA), while credit amendments vary (PEDEVCO expanded to $250M max, Investcorp cut to $50M). Forward-looking catalysts cluster in Q3 2026 (merger closes, asset sales) and Nov 2026 (listing cures), with no insider trading reported but governance shifts (Permian Basin majority vote amendments) easing future changes. Overall, distress signals are concentrated in small-cap biotechs/miners (listing risks, low-price financings), but broader portfolio shows proactive refinancing amid no outright bankruptcies, implying turnaround potential vs deepening insolvency.

47 high priority 47 total filings
· daily

US Executive Officer Management Changes SEC — May 08, 2026

Across 50 filings from May 8, 2026, focused on USA executive and director changes, the dominant theme is annual shareholder meetings (20+ companies) with strong approvals for director elections (avg 90%+ FOR votes), say-on-pay (avg 85%+ approval), and equity plans, signaling robust governance alignment amid stable financial health implied by auditor ratifications. Notable cluster of CFO resignations and appointments at Franklin Templeton ETF sponsors (6 filings: Bitcoin, Crypto, Solana, Ethereum, Gold, XRP), all neutral and non-dispute related, suggesting routine sponsor-level transitions without operational discord. Positive executive appointments dominate (e.g., ex-Macy's CEO at Signet, biotech veteran at iBio, Precision Castparts CFO at CPS Tech), with sentiments positive in 12/50 filings, contrasting rare negative cases like Cyber Enviro-Tech CFO exit. Retention incentives (Timken GC to 2028) and performance RSUs (Sonic Automotive) highlight management conviction, while planned retirements (FHLB Boston CEO, WEC Chairman) show orderly succession. No explicit YoY/QoQ financial declines noted, but high withheld votes in gaming (Boyd 20M+ for one director) and REITs (Invitation Homes 50M+) flag potential shareholder dissent; overall, bullish stability with alpha in leadership upgrades across retail, biotech, fintech.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 08, 2026

Across 50 filings from May 8, 2026, focused on USA board room changes, a dominant theme is robust shareholder approval at annual meetings for 15+ companies (e.g., 90%+ FOR votes in Edwards Lifesciences, Ally Financial, averaging 88-99% support), signaling strong governance alignment amid board refreshes via retirements and elections. C-suite transitions cluster in finance roles, with 12 CFO/CAO changes (e.g., identical swaps at 6 Franklin ETFs, Playtika's permanent CFO appointment), mostly neutral but positive for experienced hires like CPS Technologies' Chris Fraser from Berkshire subsidiary. Positive sentiments prevail (24/50 filings), driven by high-profile board adds (Signet Jewelers' ex-Macy's CEO, iBio's biotech MD, Butterfly Network's medtech vet) and promotions (HealthStream COO), contrasting isolated negative signals like CFO resignations at Cyber Enviro-Tech and Robinhood CTO separation. No explicit YoY financial declines noted, but high withhold votes (e.g., 20M+ at Boyd Gaming, 54M at Invitation Homes) flag pockets of dissent; equity grants and retention deals (e.g., Timken EVPG&C, Sonic Automotive PSUs) indicate retention focus. Portfolio-level pattern: small-cap/ETF churn vs large-cap stability suggests sector rotation opportunities; implications include enhanced strategic execution from retail/biotech expertise amid no reported guidance cuts.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 08, 2026

The 10 filings reveal a dynamic SPAC-heavy M&A landscape with 7/10 involving blank-check companies at various lifecycle stages: new IPOs injecting $220M fresh capital (Collective), extensions (byNordic to June 12), compliance meetings (Melar June 16), distress signals (Alchemy suspension May 14), and debt maneuvers (Quetta $1.04M release, Black Hawk $300K note). Completed transactions dominate materiality, including take-privates/mergers (Cantaloupe at $11.20/share, European Wax at $5.80/share EV $640M) and deSPAC (AParadise), alongside a distressed asset sale (Cannabist $16.5M Delaware ops). Period-over-period trends are sparse but stark: AParadise Q1 2026 net loss surged 396% YoY to $16.4M from $3.3M, with op ex up sharply and $19M cash burn, flagging post-deSPAC weakness. No insider trading reported across filings; capital allocation leans toward deleveraging (Quetta) or funding extensions (Black Hawk/byNordic). Market implications: SPAC distress creates short opportunities, while completions validate PE buyouts in consumer/services; portfolio trend of 4/10 positive sentiments signals selective M&A momentum amid bankruptcy risks.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 08, 2026

Across 50 overnight SEC filings for May 7-8, 2026, Q1 2026 results dominate with mixed sentiments (28/50 mixed), showing revenue growth averaging +15% YoY in high performers like Cloudflare (+33.5%), Astrana Health (+56%), and Monster Beverage (+26.9%), but declines in REITs (NewLake -6.8%) and consumer (Nu Skin -12.1%), amid margin compression in 12/20 reporting companies (avg -150bps). Capital allocation trends bullish with 8 dividend declarations/hikes (e.g., Innospec +10%, Grainger +10%) and buybacks (Yum China $218M, Grainger $345M returned), while financings raised $200M+ (Cellectar $35M, Comstock $57.5M). Energy/mining sector volatile with production ramps (Gold Resource +158% AuEq sold) offset by losses (Gran Tierra -$119M), tech pivots to AI (IREN $3.4B NVIDIA deal), and healthcare/biotech catalysts (Cellectar Phase 3 trial funding). Guidance raised in 6 firms (Grainger EPS to $44.25-46.25, Playtika revenue $2.75-2.85B), signaling resilience; portfolio-level trend: op cash flow improved in 14/25 (avg +25% YoY) despite debt rises (Ducommun +25%). Critical implications: Favor growth tech/health over cyclical REITs/energy pre-market; watch AI/energy transitions for alpha.

21 high priority 29 medium 50 total filings
· daily

DHS Homeland Security Contracts — May 07, 2026

DHS awarded $137,275,599 in contracts to Palantir Technologies Inc. ($86M) and The GEO Group, Inc. ($51M), representing a fully civilian stream (0/2 defense-related) focused on ICE's Enforcement Removal Operations modernization and detention services. The dominant theme is ICE's investment in IT SaaS platforms and security guard services under full and open competition, with Palantir's $86M BPA call emerging as the highest-conviction bullish signal due to its superior materiality (7/10). Both firm fixed price awards carry high pricing risk with $0 outlays to date, signaling pre-execution phases. Investors should watch outlay progress and performance starts in 2026 for revenue realization confirmation.

2 total filings
· daily

VA Healthcare & Services Contracts — May 07, 2026

The VA Healthcare & Services stream saw $159,996,058 in total obligations across two contracts, entirely civilian with 0/2 defense-related and average signal strength of 4.0/10. Dominant agency is Department of Veterans Affairs, focusing on medical disability examinations ($106M to Veterans Evaluation Services, Inc.) and health IT encoder software/support ($54M to Solventum Health Information Systems, Inc., 3M subsidiary). Both are neutral signals from full and open competition firm-fixed price awards, with VES showing substantial $94.3M outlay execution on its completed 2021 contract and Solventum at $23.9M outlay on its ongoing award to potential 2026 end. Highest-conviction signal is VES's high execution rate indicating revenue reliability for veteran-owned providers. Key risk: high pricing risk on firm-fixed structures and post-2021 re-compete vulnerability for VES.

2 total filings
· daily

New Federal Contractors — May 07, 2026

This digest synthesizes 18 new federal contracts totaling $1,337,470,948 in obligations from May 07, 2026, overwhelmingly civilian (17/18) with only ABSS SOLUTIONS INC's $113M biomedical R&D at Lackland AFB defense-related via GSA. Dominant themes include IT modernization and engineering services for HHS/CMS (VENTERA LLC $84M, Flexion Inc $49M), DHS/ICE (Palantir Technologies Inc $86M, THE GEO GROUP $51M), and DOE (BWXT Nuclear Operations Group $80M HALEU processing). Highest-conviction bullish signal is BWXT's $80M non-competed DOE award with $56M outlayed, signaling nuclear moat durability. Key risk is high fixed-price execution exposure across $1B+ obligations (e.g., VETERANS EVALUATION SERVICES $106M fully committed but past-dated) and $0 outlays on future contracts like Palantir and Olsson Industrial Electric ($69M). Watch multi-year option exercises amid civilian agency budget cycles.

18 total filings
· daily

Significant Contract Modifications ($10M+) — May 07, 2026

These 18 significant contract modifications totaling $1,337,470,948 in obligations are overwhelmingly civilian (17/18 contracts, ~99.9% value), with only ABSS Solutions' $113M GSA award at Lackland AFB qualifying as defense-related. Dominant themes include IT/services for HHS/CMS (VENTERA $84M, Flexion $49M), DHS/ICE (Palantir $86M, GEO Group $51M), and DOE (BWXT $80M HALEU processing), alongside engineering/health R&D across VA, NOAA, and NASA. Highest-conviction bullish signal is BWXT Nuclear Operations Group's $79.8M DOE NNSA non-competed HALEU processing award (strength 7/10, materiality 8/10), signaling durable nuclear revenue through 2028. Key risk is pervasive high fixed-price execution risk across 12+ contracts (e.g., VES $106M VA fully committed but past-dated), compounded by $0 outlays on future-dated awards like Palantir and Olsson ($68.7M Interior). Watch multi-year option exercises, especially VENTERA's $18M upside to $102M CMS ceiling.

18 total filings
· daily

Contract Deobligations Alert — May 07, 2026

This Contract Deobligations Alert captures $1,337,470,948 in total obligations across 18 contracts on May 07, 2026, with only 1 defense-related (ABSS Solutions at Lackland AFB via GSA) and 17 civilian-focused awards spanning agencies like GSA, VA, DHS, DOE, and HHS. Dominant themes include civilian IT modernization and health/services support, with bullish signals concentrated in multi-year delivery orders for Palantir ($86M DHS ICE SaaS), BWXT ($80M DOE HALEU processing), and Lynker ($99M Commerce NOAA). Highest-conviction bullish signal is BWXT Nuclear Operations Group's $79.8M non-competed DOE award for specialized HALEU processing through 2028, signaling durable nuclear revenue amid DOE priorities. Key risk is high fixed-price execution exposure across 12 contracts (e.g., VES $106M VA, Olsson $69M Interior), compounded by $0 outlays on four future-dated awards totaling $277M (Palantir, GDIT, Olsson, GEO). Watch multi-year option exercises and outlay ramps on top materiality contracts.

18 total filings
· daily

Contract Option Exercises — May 07, 2026

This digest synthesizes 18 contract option exercises totaling $1,337,470,948 in obligations, with only 1/18 defense-related (Booz Allen Hamilton's $112.7M GSA award for Army SETA services) and the rest civilian-led by agencies including GSA, VA, DHS, HHS, and DOE. Dominant themes center on civilian IT modernization, health services, and environmental/nuclear support, with no clear defense acceleration. Highest-conviction bullish signal is BWXT Nuclear Operations Group's $79.8M DOE NNSA award for HALEU processing (strength 7/10, materiality 8/10), signaling durable nuclear revenue through 2028. Key watch item: Progress on zero-outlay future-dated contracts like Palantir's $86.3M DHS ICE BPA (starts 2026) and GEO Group's $51M DHS detention services, amid high firm-fixed-price execution risks across 70%+ of awards.

18 total filings